中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

174 records (took 0.022 seconds)

    HMO PRODUCTION
    64.
    发明公开
    HMO PRODUCTION 审中-公开

    公开(公告)号：US20230227876A1

    公开(公告)日：2023-07-20

    申请号：US17759273

    申请日：2021-01-22

    Applicant: GLYCOM A/S

    Inventor： Margit PEDERSEN ,  Katrine Bych KAMPMANN

    IPC: C12P19/00 ,  C07K14/24

    CPC classification number: C12P19/00 ,  C07K14/24

    Abstract: The present invention relates to the field of recombinant production of biological molecules in host cells. More particularly it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS).

    Synthetic composition for microbiota modulation
    65.
    发明授权
    Synthetic composition for microbiota modulation 有权

    公开(公告)号：US11696921B2

    公开(公告)日：2023-07-11

    申请号：US17001118

    申请日：2020-08-24

    Applicant: GLYCOM A/S

    Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell

    IPC: A61K31/702 ,  A61P3/04 ,  A61P3/10 ,  A61P1/00 ,  A61K9/00

    CPC classification number: A61K31/702 ,  A61K9/0053 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10

    Abstract: A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro¬intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.

    SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V
    70.
    发明申请
    SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V 有权

    公开(公告)号：US20220282262A1

    公开(公告)日：2022-09-08

    申请号：US17299583

    申请日：2019-12-04

    Applicant: GLYCOM A/S

    Inventor： Manos PAPADAKIS ,  Margit PEDERSEN

    IPC: C12N15/70 ,  C12N9/10 ,  C12P19/18

    Abstract: The present invention provides a method for biotechnological production of LNFP-V by using recombinant bacterial cells. LNFP-V is produced by using a polypeptide having an a1,3/4-fucosyl transferase activity and comprising or consisting of an amino acid sequence that has a sequence identity of at least 90% with amino acid sequence of SEQ ID No. 1 or 3.

Patent Agency Ranking